Iantrek Raises $42 Million in Series C Funding to Launch Interventional Glaucoma Therapy

WHITE PLAINS, N.Y.—Iantrek, Inc., a medical technology company developing bio-interventional approaches for chronic eye diseases, has announced the close of a $42 million Series C financing round, which the company said will fund the U.S. commercial launch of AlloFlo Uveo, a surgical solution targeting the uveoscleral pathway, as well as broader pipeline expansion. According to the announcement, the Series C was led by U.S. Venture Partners (USVP), joined by aMoon Fund, along with existing investors Visionary Ventures, Sectoral Asset Management, Radius Special Situations Fund, and Civilization Ventures.